Results 51 to 60 of about 23,486 (164)
Italian Journal of Medicine, 2013 Patients undergoing total hip arthroplasty or total knee arthroplasty have a high risk for post-operative venous thromboembolism. The current study addressed the use of fondaparinux post-operatively in 556 patients with antiplatelet therapy in order to ...
Guido Grappiolo +5 more
doaj +1 more source
Journal of the American Geriatrics Society, Volume 74, Issue 6, Page 1841-1844, June 2026.Cannabis use in older adults may have a broad range of effects in older adults impacting Mind, Mobility, Medications, Multi‐complexity, and what Matters Most.
Erik Fraunberger, Maia von Maltzahn
wiley +1 more source
Management of acute coronary syndromes with fondaparinux
Vascular Health and Risk Management, 2007 Harm Wienbergen, Uwe ZeymerHerzzentrum Ludwigshafen, Medizinische Klinik B, GermanyAbstract: Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use.
Harm Wienbergen, Uwe Zeymer
doaj
Beyond the Thrombus: Imaging‐Guided Management of Acute Coronary Syndrome
Clinical Case Reports, Volume 14, Issue 5, May 2026.Imaging‐guided management of acute coronary syndrome. ABSTRACT Intracoronary imaging is a true game‐changer in acute coronary syndromes, enhancing diagnostic accuracy while ensuring precise, mechanism‐driven, and patient‐tailored management.
Guillaume Guebey +5 more
wiley +1 more source
Fitusiran treatment modulates the ratio between alpha‐ and beta‐antithrombin isoforms
HemaSphere, Volume 10, Issue 5, May 2026.Abstract Antithrombin (AT) circulates as two distinct isoforms, alpha‐ and beta‐AT, which differ in their glycosylation profiles; alpha‐AT is fully glycosylated at positions Asn128, Asn167, Asn187, and Asn224, whereas beta‐AT lacks Asn167 glycosylation.
Geneviève McCluskey +10 more
wiley +1 more source
BMC Cardiovascular Disorders, 2017 Background Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS).
Pravesh Kumar Bundhun +2 more
doaj +1 more source
Fucoidan: An Update on Function, Role in Human Health and Applications
Chemical Biology &Drug Design, Volume 107, Issue 5, May 2026.Fucoidan is a promising bioactive compound with anti‐inflammatory, anticoagulant, anticancer, antioxidant, antiviral, and cardioprotective properties. In addition, thanks to its epigenetic potential, ability to modulate autophagic mechanisms and possibility adjuvant agent or bioactive component of the drug delivery systems, fucoidan is a promising ...
Sharon Critelli, Marilena Celano
wiley +1 more source
Archiv der Pharmazie, Volume 359, Issue 4, April 2026.Fully synthetic sulfated non‐carbohydrate polymers for structurally mimicking the polysaccharide glycosaminoglycan heparin in its anticoagulant activities with further prospects to pleiotropic effects in oncology and in antiviral approaches. ABSTRACT Heparin is one of the oldest drugs on the market.
Katrin Nekipelov +2 more
wiley +1 more source
Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders
International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 259-271, April 2026.ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley +1 more source
FONDAPARINUX IN THE TREATMENT OF ACUTE CORONARY SYNDROME
Атеротромбоз, 2017 Fondaparinux is a parenteral selective factor-Xa inhibitor. The drug is successfully used in the treatment of acute coronary syndrome, and is characterized by the ideal profile of effectiveness and safety. In the case of ACS without ST-segment elevation,
O. O. Shakhmatova
doaj +1 more source